Clinipace Clinical Research Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.20 M
- Company Age 21 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 293.39%
- Profit Growth -90.84%
- Ebitda 17.62%
- Net Worth 1.64%
- Total Assets 2.70%
About Clinipace Clinical Research
Clinipace Clinical Research Private Limited (CCRPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 03 December 2003 and has a history of 21 years and two months. Its registered office is in Thiruvananthapuram, Kerala, India.
The Corporate was formerly known as Indatum Research Data Services Private Limited. The Company is engaged in the Information Technology Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Vinod Puthenpureckal, Uma Jayadevan, Simone Brown, and One other member serve as directors at the Company.
Company Details
-
Location
Thiruvananthapuram, Kerala, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U72400KL2003PTC016661
-
Company No.
016661
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
03 Dec 2003
-
Date of AGM
28 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at Clinipace Clinical Research?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vinod Puthenpureckal
|
Director | 18-Jul-2011 | Current |
|
Uma Jayadevan
|
Alternate Director | 17-Jan-2023 | Current |
| Simone Brown | Director | 06-Jan-2023 | Current |
David Rifkind
|
Director | 06-Jan-2023 | Current |
Financial Performance of Clinipace Clinical Research.
Clinipace Clinical Research Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 293.39% increase. The company also saw a substantial fall in profitability, with a 90.84% decrease in profit. The company's net worth moved up by a moderate rise of 1.64%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Clinipace Clinical Research?
In 2023, Clinipace Clinical Research had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Clinipace Clinical Research?
Clinipace Clinical Research has a workforce of 229 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Clinipace Clinical Research, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Clinipace Clinical Research's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
